XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements and Licensing Agreements, Roche (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Agreement
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Agreement
Jun. 30, 2023
USD ($)
Jul. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 225,250 $ 188,411 $ 344,748 $ 318,935    
Roche [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 3   3      
Revenue $ 11,089 $ 5,754 $ 22,595 $ 8,121    
Deferred contract revenue $ 15,000   $ 15,000     $ 36,700
Roche [Member] | Revenue [Member] | Strategic Partner [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Concentration percentage 5.00% 3.00% 7.00% 3.00%    
Roche [Member] | Minimum [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Cumulative payments received $ 345,000   $ 345,000      
HD [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 1   1      
IONIS-FB-L for Complement-Mediated Diseases [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 1   1      
IONIS-FB-L for Complement-Mediated Diseases [Member] | Subsequent Event [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Maximum amount of payments receivable over term of collaboration         $ 430,000  
Maximum amount of license fees over term of collaboration         35,000  
Maximum amount of development milestone payments over term of collaboration         25,000  
Maximum amount of regulatory milestone payments over term of collaboration         90,000  
Maximum amount of sales milestone payments over term of collaboration         280,000  
Next payment to be achieved         $ 23,500  
RNA-targeted Programs for AD and HD [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 1   1